Nigpa Pharma Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 24-12-2024
- Paid Up Capital ₹ 4.91 M
as on 24-12-2024
- Company Age 33 Year, 10 Months
- Last Filing with ROC 31 Mar 2016
- Open Charges ₹ 8.77 M
as on 24-12-2024
- Revenue 14.87%
(FY 2016)
- Profit 44.67%
(FY 2016)
- Ebitda 194.42%
(FY 2016)
- Net Worth -14.11%
(FY 2016)
- Total Assets -8.69%
(FY 2016)
About Nigpa Pharma
The Corporate was formerly known as Nigpa Pharma Limited. The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2016. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 4.91 M.
The company currently has active open charges totaling ₹8.77 M.
Priti Mandlecha, Nirmala Mandlecha, Banechand Mandalecha, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230MH1991PTC060674
- Company No.
060674
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Mar 1991
- Date of AGM
30 Sep 2016
- Date of Balance Sheet
31 Mar 2016
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nigpa Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumit Mandlecha  | Managing Director | 31-Mar-2010 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Priti Mandlecha | Director | 31-Mar-2010 | Current |
| Nirmala Mandlecha | Director | 31-Mar-2010 | Current |
| Banechand Mandalecha | Director | 08-Mar-1991 | Current |
Financial Performance of Nigpa Pharma.
Nigpa Pharma Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 14.87% increase. The company also saw a substantial improvement in profitability, with a 44.67% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nigpa Pharma?
In 2016, Nigpa Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Malkpur Urban Co-Op. Bank Ltd Creation Date: 04 Jul 2008 | ₹2.50 M | Open |
Malkpur Urban Co-Op. Bank Ltd Creation Date: 04 Jul 2008 | ₹2.50 M | Open |
Maharashtra State Financial Corporation Creation Date: 19 Mar 1994 | ₹3.54 M | Open |
How Many Employees Work at Nigpa Pharma?
Nigpa Pharma has a workforce of 0 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nigpa Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nigpa Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
